Alvotech Appoints Experienced Life-Science Analyst Patrik Ling As Vice President, Investor Relations Scandinavia

Alvotech, a global biotechnology company dedicated to biosimilar medicines, announced the appointment of Patrik Ling as Vice President, Investor Relations Scandinavia. Ling will be based in Stockholm and will focus on strengthening the company’s engagement with investors in the Nordic region.

“This is a truly exciting time to join Alvotech, with its expanding portfolio of products in the market and in development, supported by a new base of R&D operations in Sweden. Biosimilars play an important role in meeting the growing demand for high-quality biologics and controlling the escalating cost of healthcare. I look forward to engaging with Scandinavian investors, helping them to better understand Alvotech’s strengths and value proposition,” said Patrik Ling.

Ling brings over 25 years of experience in the life-science industry. Before joining Alvotech, he worked as a Senior Equity Analyst at investment bank DNB Carnegie, where he covered numerous life science companies, including Alvotech. Earlier in his career, he worked in pharmaceutical marketing and sales, later transitioning into the financial sector as a portfolio manager and equity analyst specialising in life sciences.

“It is a great pleasure to have Patrik on board, as he’s been following Alvotech closely over the years and is a highly respected expert within the life science industry in Scandinavia. Patrik’s background in both pharma and finance, will be a great asset to our team as we continue to broaden our shareholder base in Scandinavia and affirm Alvotech’s role as a leading life science company in the Nordics,” said Róbert Wessman, chairman and CEO of Alvotech.  

Founded by Róbert Wessman, Alvotech is exclusively focused on developing and manufacturing biosimilars. The company has biosimilars to Humira® (adalimumab) and Stelara® (ustekinumab) already approved and marketed globally. Its pipeline currently includes nine biosimilar candidates targeting conditions such as autoimmune and eye disorders, osteoporosis, respiratory diseases, and cancer.